Boditech Med Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
5,379
8,587
1,986
12,311
3,139
Depreciation, Depletion & Amortization
896
1,249
1,577
2,442
3,629
Other Funds
-
431
1,221
4,262
43
Funds from Operations
6,126
10,180
13,359
14,658
5,381
Changes in Working Capital
858
2,524
3,726
2,867
4,495
Net Operating Cash Flow
5,268
7,656
9,632
11,791
887
Capital Expenditures
6,669
3,783
10,558
9,826
6,695
Sale of Fixed Assets & Businesses
-
-
14
1,594
2,293
Purchase/Sale of Investments
2,812
3,385
9,071
7,142
8,446
Net Investing Cash Flow
11,172
8,398
3,014
15,040
16,860
Cash Dividends Paid - Total
-
-
-
2,365
2,094
Issuance/Reduction of Debt, Net
5,680
3,568
400
50
28,342
Net Financing Cash Flow
14,672
4,139
1,620
171
25,602
Net Change in Cash
8,770
4,893
8,224
3,357
9,741
Free Cash Flow
631
4,614
278
3,560
5,097
Net Assets from Acquisitions
-
-
-
15,062
4,426
Other Sources
596
966
1,810
3,400
5,008
Change in Capital Stock
8,992
1,003
1
2,118
604
Exchange Rate Effect
1
11
15
64
112
Other Uses
2,287
2,196
3,351
2,288
4,594

About Boditech Med

View Profile
Address
43 Geodudanji 1-gil
Chuncheon GA 24398
Korea, Republic Of
Employees -
Website http://www.boditech.co.kr
Updated 09/14/2018
Boditech Med, Inc. engages in the provision of in-vitro diagnostics analyzers and reagents. Its products include iChroma II Reader, AFIAS6, iChroma Reader, Ichroma D, i-Chamber, and hemochroma PLUS. It also provides cardiac, tumor, diabetes, hormone, infection and rheumatoid arthritics tests.